Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Account Payables (2021 - 2025)

Kiniksa Pharmaceuticals International's Change in Account Payables history spans 5 years, with the latest figure at -$4.1 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 34.4% year-over-year to -$4.1 million; the TTM value through Dec 2025 reached $142000.0, up 102.25%, while the annual FY2025 figure was $142000.0, 102.25% up from the prior year.
  • Change in Account Payables reached -$4.1 million in Q4 2025 per KNSA's latest filing, down from -$2.7 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $7.2 million in Q4 2023 to a low of -$6.5 million in Q1 2023.
  • Average Change in Account Payables over 5 years is $79000.0, with a median of $67000.0 recorded in 2021.
  • Peak YoY movement for Change in Account Payables: surged 2472.0% in 2022, then tumbled 529.57% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at $250000.0 in 2021, then soared by 2472.0% to $6.4 million in 2022, then grew by 12.5% to $7.2 million in 2023, then crashed by 186.87% to -$6.3 million in 2024, then soared by 34.4% to -$4.1 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Change in Account Payables are -$4.1 million (Q4 2025), -$2.7 million (Q3 2025), and $6.9 million (Q2 2025).